Developing and advancing dry powder inhalation towards enhanced therapeutics

Adams, 2012, Effects of device and formulation on in vitro performance of dry powder inhalers, AAPS J., 14, 400, 10.1208/s12248-012-9352-7 Adams, 2010, Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report, J Aerosol Med Pulmonary Drug Del, 23, 1, 10.1089/jamp.2009.0803 Afonso, 2011, COPD in the general population: prevalence, incidence and survival, Respir. Med., 105, 1872, 10.1016/j.rmed.2011.06.012 Anderson, 2005, History of aerosol therapy: liquid nebulization, to MDIs to DPIs, Respir. Care, 50, 1139 Arvidsson, 2000, Equivalnet therapeutic ratio of salbutamol given by Turbohaler® and Diskus™, Respir. Med., 94, 574, 10.1053/rmed.1999.0778 Bagger-Jörgensen, 2005, Effect of inherent variability of inhalation products on impactor mass balance limits, J. Aerosol. Med., 18, 367, 10.1089/jam.2005.18.367 Begat, 2004, The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics, Pharm. Res., 21, 1826, 10.1023/B:PHAM.0000045236.60029.cb Benson, 2004, From good manufacturing practice to good manufacturing performance, Pharm. Eng., 24, 26 Bresges, 2008, Determination of the minimum number of spacer particles ensuring non-contact between host particles – a new approach by numerical modelling, Powder Technol., 187, 260, 10.1016/j.powtec.2008.03.002 Blasi, 2009, Fighting tuberculosis: old drugs, new formulations, Exp. Opin. Drug Del., 6, 977, 10.1517/17425240903130577 Blondal, 2011, Countrywide management of pulmonary tuberculosis reverses increasing incidence, Int. J. Tuberc. Lung Dis., 15, 892, 10.5588/ijtld.10.0601 Borgström, 1996, The inhalation device influences lung deposition and bronchodilating effect of terbutaline, Am. J. Respir. Crit. Care Med., 153, 1636, 10.1164/ajrccm.153.5.8630614 Borgström, 1990, A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline, Pharm. Res., 7, 1068, 10.1023/A:1015951402799 Boshhiha, 2009, Influence of carrier syrface fines on dry powder inhalation formulations, Drug. Dev. Ind. Pharm., 35, 904, 10.1080/03639040802698794 Bousquet, 2007, Global alliance against chronic respiratory diseases, Eur. Respir. J., 29, 233, 10.1183/09031936.00138606 Bousquet, J., Khaltaev, N., 2007. Global surveillance, prevention and control of chronic respiratory diseases. World Health Organization. <http://www.who.int/respiratory/publications/global_surveillance/en/index.html>. Brannan, 2009, Inhaled mannitol as a test for bronchial hyper-resonsiveness, Expert. Rev. Respir. Med., 3, 457, 10.1586/ers.09.38 Byron, 2010, In vivo–in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols, J. Aerosol. Med. Pulmonary. Drug Del., 23 Bur, 2010, Drug transport across pulmonary epithelial cell monomayers: effect of particle size, apical liquid volume, and deposition technique, J. Aerosol. Med. Pulmonary Drug Del., 23, 119, 10.1089/jamp.2009.0757 Center of Disease Control, 2011. Vital signs: asthma prevalence, disease characteristics, and self-management education – United States, 2001–2009. MMWR, vol. 60(17), pp. 547–552. Chan, 2008, What is the role of particle morphology in pharmaceutical powder aerosols?, Expert. Opin. Drug Deliv., 5, 909, 10.1517/17425247.5.8.909 Chew, 2005, Effect of amino acids on the dispersion of disodium cromoglycate powders, J. Pharm. Sci., 94, 2289, 10.1002/jps.20426 Chow, 2007, Particle engineering for pulmonary drug delivery, Pharm. Res., 24, 411, 10.1007/s11095-006-9174-3 Coates, 2006, Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: air inlet size, J. Pharm. Sci., 95, 1382, 10.1002/jps.20603 Coates, 2007, Influence of mouth piece geometry on the aerosol delivery performance of a dry powder inhaler, Pharm. Res., 24, 1450, 10.1007/s11095-007-9262-z Coates, 2005, The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses, Pharm. Res., 22, 923, 10.1007/s11095-005-4587-y Cogdill, 2007, The financial returns in investments in process analytical technology and lean manufacturing: benchmarks and case study, J. Pharm. Innov., 2, 38, 10.1007/s12247-007-9007-x Concessio, 1999, Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamics effect, Pharm. Res., 16, 828, 10.1023/A:1018865717374 Daley-Yates, 2010, The clinical utility of pharmacokinetics in demonstrating bioequivalence of locally acting orally inhaled drugs, Respir. Drug Deliv., 1, 273 De Koning, 2002, Effect of an external resistance to airflow on the inspiratory flow curve, Int. J. Pharm., 234, 257, 10.1016/S0378-5173(01)00969-3 Dhanda, 2005, Metered dose inhalers (MDIs) and dry powder inhalers (DPIs) for pulmonary drug delivery: CMC issues, Clin. Res. Regul. Affairs, 22, 31, 10.1081/CRP-62268 Edge, 2008, Factors affecting defining the quality and functionality of excipients used in the manufacture of dry powder inhaler products, Drug Dev. Ind. Pharm., 34, 966, 10.1080/03639040802192814 Edwards, 2010, Applications of capsule dosing techniques for use in dry powder inhalers, Ther. Deliv., 1, 195, 10.4155/tde.10.1 Eklund, 2008, Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults, Biopharm. Drug Dispos., 29, 382, 10.1002/bdd.622 El-Gendy, 2011, Nanoparticle agglomerates of fluticasone proprionate in combination with albuterol sulfate as dry powder aerosols, Eur. J. Pharm. Sci., 44, 522, 10.1016/j.ejps.2011.09.014 EMA, 2005. Guidelines on the Pharmaceutical Quality of Inhaled and Nasal Products. EMEA/CHMP/QWP/49313/2005 Corr. EMA, 2009. Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence Between Two Inhaled Products for use in the Treatment of Asthma and Chronic Obstructive Pulmonary disease (COPD) in Adults and for use in the Treatment of Asthma in Children and Adolescents. CPMP/EWP/4151/00 Rev. 1. EMEA, 2009. Overview of Comments Received on ‘Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence Between two Inhaled Products for use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD)’ (CPMP/EWP/4151/00 Rev. 1). EMEA/CHMP/EWP/187653/2009 <http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/09/WC500096775.pdf>. Eskandar, 2011, Low powder mass filling of dry powder inhalation formulations, Drug Dev. Ind. Pharm., 37, 24, 10.3109/03639045.2010.489561 Evans, 2012, Equivalence considerations for orally inhaled products for local action – ISAM/IPAC-RS European Workshop Report, J. Aerosol. Med. Pulmonary Drug. Deliv., 25, 117, 10.1089/jamp.2011.0968 Fattorini, 1999, Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis, Microb. Drug Resist., 5, 260, 10.1089/mdr.1999.5.265 FDA, 1998. Guidance to the Industry Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products. Chemistry, Manufacturing and Control Documentation. X:⧹CDERGUID⧹2180DFT.WPD. Fiegel, 2008, Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin, Pharm. Res., 25, 805, 10.1007/s11095-007-9381-6 Freedman, 1956, Medihaler therapy for bronchial asthma: a new type of aerosol therapy, Postgrad. Med. J., 20, 667, 10.1080/00325481.1956.11691366 Galitsky, C., Chang, S.-C., Worrell, E., Masanet, E., 2006. Improving Energy Efficiency in Pharmaceutical Manufacturing Operations. Ernest Orlando Lawrence Berkley National Laboratory (LBNL-60288). Ganderton, 1997, General factors influencing drug delivery to the lung, Respir. Med., 91, 13, 10.1016/S0954-6111(97)90099-8 Garcia-Contreras, 2007, Inhaled lareg porous particles of capreomycin for treatment of tuberculosis in a guinea pig model, Antimicrob. Agents Chemother., 51, 2830, 10.1128/AAC.01164-06 Geller, 2011, Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology, J. Aerosol. Med. Pulmonary Drug Del., 24, 175, 10.1089/jamp.2010.0855 Gershon, 2010, Trends in asthma prevalence and incidence in Ontario, Canada, 1996–2005: a population study, Am. J. Epidemiol., 172, 728, 10.1093/aje/kwq189 Giovagnoli, 2007, Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery, Int. J. Pharm., 333, 103, 10.1016/j.ijpharm.2006.10.005 Groneberg, 2003, Fundamentals of pulmonary drug delivery, Respir. Med., 97, 382, 10.1053/rmed.2002.1457 Guo, 2008, Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen Cascade Impactor and the Next Generation Pharmaceutical Impactor, J. Pharm. Sci., 97, 3321, 10.1002/jps.21203 Hämmerlein, 2011, Pharmacist-led intervention study to improve inhalation technique in asthma and COPD patients, J. Eval. Clin. Pract., 17, 61, 10.1111/j.1365-2753.2010.01369.x Haghi, 2012, Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia, Mol. Pharm., 9, 1717, 10.1021/mp200620m Harrison, 2003, Plasma concentrations of fluticonasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects, Thorax, 58, 258, 10.1136/thorax.58.3.258 Hassan, 2010, Effect of particle formulation on dry powder inhalation efficiency, Curr. Pharm. Des., 16, 2377, 10.2174/138161210791920423 Heifets, 2005, Capreomycin is active against non-replicating M. tuberculosis, Ann. Clin. Microbiol. Antimicrob., 4, 6, 10.1186/1476-0711-4-6 Hein, 2011, A new pharmaceutical aerosol deposition device on cell cultures (PADDDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations, Eur. J. Pharm. Sci., 77, 132 Holsapple, 2005, Research strategies for safety evaluation of nanomaterials, Part II: toxicology and safety evaluation of nanomaterials, current challenges and data needs, Toxicol. Sci., 88, 12, 10.1093/toxsci/kfi293 Hooton, 2008, The influence of crystal habit on the prediction of dry powder inhalation formulation performance using the cohesive-adhesive force balance approach, Drug Dev. Ind. Pharm., 34, 974, 10.1080/03639040802149087 Islam, 2008, Dry powder inhalers (DPI) – a review of device reliability and innovation, Int. J. Pharm., 360, 1, 10.1016/j.ijpharm.2008.04.044 Janssens, 2008, Inspiratory flow rates at different levels of resistance in elderly COPD patients, Eur. Respir. J., 31, 78, 10.1183/09031936.00024807 Jones, 2006, The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations, Pharm. Res., 23, 1665, 10.1007/s11095-006-9012-7 Jones, 2010, The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance, Int. J. Pharm., 391, 137, 10.1016/j.ijpharm.2010.02.031 Kitamaru, M., 2012. Glaxo tests cheaper version of Advair for emerging markets. Bloomberg, (9.2.12). Labiris, 2003, Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications, Brit. J. Clin. Pharmacol., 56, 600, 10.1046/j.1365-2125.2003.01893.x Laube, 2005, The expanding role of aerosol in systemic drug delivery, gene therapy, and vaccination, Respir. Care, 50, 1161 Le, 2012, Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate, AAPS PharmSciTech, 13, 477, 10.1208/s12249-012-9765-8 Leach, 2005, The CFC to HFA transition and its impact on pulmonary drug development, Respir. Care, 50, 1201 Lecaillon, 1999, Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of foradil dry powder inhalation via aerolizer™, Eur. J. Clin. Pharmacol., 55, 131, 10.1007/s002280050607 Lee, 2009, In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases, AAPS J., 11, 414, 10.1208/s12248-009-9121-4 Li, 2010, Nanoparticles by spray drying using innovative new technology: the Büchi nano spray dryer B-90, J. Control. Release, 147, 304, 10.1016/j.jconrel.2010.07.113 LiCalsi, 1999, Dry powder inhalation as a potential delivery method for vaccines, Vaccines, 17, 1796, 10.1016/S0264-410X(98)00438-1 Mannino, 2007, Global burden of COPD: risk factors, prevalence, and future trends, Lancet, 370, 765, 10.1016/S0140-6736(07)61380-4 Marek, 2011, Effects of mild processing pressures on the performance of dry powder inhaler formulations for inhalation therapy (1): budesonide and lactose, Eur. J. Pharm. Biopharm., 78, 97, 10.1016/j.ejpb.2010.12.020 Matida, 2006, Improving prediction of aerosol deposition in an idealized mouth using Large Eddy Simulation, J. Aerosol. Med., 19, 290, 10.1089/jam.2006.19.290 Melani, 2004, Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults, Ann. Allergy Asthma Immunol., 93, 433, 10.1016/S1081-1206(10)61410-X Mitchell, 2011, Non-impactor-based methods for sizing of aerosols emitted from orally inhaled and nasal drug products (OINDPs), AAPS PharmSciTech, 12, 965, 10.1208/s12249-011-9662-6 Mitchell, 2007, In vitro and in vivo aspects of cascade impactor test and inhaler performance. A review, AAPS PharmSciTech, 8, E1, 10.1208/pt0804110 Musafiri, 2011, Prevalence of atopy, asthma and COPD in an urban and a rural area of an African country, Respir. Med., 105, 1596, 10.1016/j.rmed.2011.06.013 Mykhaylova, V., Dresely, K., Klar, F., Urbanetz, N.A., 2011, Carrier-free formulation of dry powder inhalates – nanoparticle coating of drug microparticles, Pharmind 7, 1324–1331. Newman S., 2009. Respiratory Drug Delivery. Essential Theory & Practice. RDD online, Richmond, Virginia (USA), pp. 69. Newman, 2004, Dry poder inhalers for optimal drug delivery, Expert. Opin. Biol. Ther., 4, 23, 10.1517/14712598.4.1.23 Newman, 1995, Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler, Pharm. Res., 12, 231, 10.1023/A:1016278926231 Niëns, 2010, Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing World, PLoS Med., 7, 1, 10.1371/journal.pmed.1000333 Nolan, 2011, Particle engineering of materials for oral inhalation by dry powder inhalers II-Sodium cromoglicat, Int. J. Pharm., 405, 36, 10.1016/j.ijpharm.2010.11.040 O’Connor, 2011, Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report, J. Aerosol. Med. Pulmonary Drug. Deliv., 24, 119, 10.1089/jamp.2011.0878 O’Donnell, 2010, High incidence of hospital admission with multidrug-resistant and extensively drug resistant tuberculosis among South African health care workers, Ann. Intern. Med., 153, 516, 10.7326/0003-4819-153-8-201010190-00008 Ooi, 2011, Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems, Int. J. Pharm., 413, 1, 10.1016/j.ijpharm.2011.04.002 Petzold, 2008, Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers, J. Aerosol. Med. Pulmonary Drug Deliv., 21, 309, 10.1089/jamp.2008.0690 Qaseem, 2011, Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society, Ann. Intern. Med., 155, 179, 10.7326/0003-4819-155-3-201108020-00008 Raula, 2008, Gas-phase synthesis of L-leucine-coated micrometer-sized salbutamol sulphate and sodium chmoride particles, Powder Technol., 289, 10.1016/j.powtec.2008.03.006 Raula, 2010, Investigations on particle surface characteristics vs. dispersion behavior of L-leucine coated carrier-free inhalable powders, Int. J. Pharm., 385, 79, 10.1016/j.ijpharm.2009.10.036 Saim, 2002, Process for overcoming drug retention in hard gelatin inhalation capsules, Drug Dev. Ind. Pharm., 28, 641, 10.1081/DDC-120003855 Salama, 2011, Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease?, Expert Opin. Pharmacother., 12, 1913, 10.1517/14656566.2011.589837 Schmekel, 1991, Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers, Thorax, 46, 225, 10.1136/thx.46.4.225 Schoubben, 2010, Simple and scalable method for peptide inhalable poxder production, Eur. J. Pharm. Sci., 39, 53, 10.1016/j.ejps.2009.10.010 Schoubben, 2011, Aerodynamic assessment and in vitro evaluation of capreomycin oleate fine powder for tuberculosis therapy, AAPS J., 13 Schoubben, 2010, Production and in vitro evaluation of hydrophocic ion pair fine powders for tuberculosis inhalation therapy, AAPS J. Selcuk, 2010, Prevalence of asthma and allergic diseases in primary school children in Edirne, Turkey, two surveys 10years apart, Pediatr. Allergy Immunol., 21, e711, 10.1111/j.1399-3038.2010.01008.x Shrestha, 2009, Comparison of bronchodilator effect of salbutamol delivered via MDI and DPI in COPD patients, SAARC J Tuber Lung Dis HIV/AIDS, VI, 22, 10.3126/saarctb.v6i2.3054 Smith, 2003, The inhaler of the future? A review of dry powder devices on the market today, Pulmonary Pharmacol. Ther., 16, 79, 10.1016/S1094-5539(02)00147-5 Son, 2010, Optimization of an in vitro dissolution test method for inhalation formulations, Dissolution Technol., 17, 6, 10.14227/DT170210P6 Son, 2008, Advancements in dry powder delivery to the lung, Drug Dev. Ind. Pharm., 34, 948, 10.1080/03639040802235902 Steckel, 2003, Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers, Eur. J. Pharm. Sci., 19, 443, 10.1016/S0928-0987(03)00148-9 Steckel, 2006, Effect of milling and sieving on functionality of dry powder inhalation products, Int. J. Pharm., 309, 51, 10.1016/j.ijpharm.2005.10.043 Stegemann, 2011, Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products, Eur. J. Pharm. Sci., 44, 447, 10.1016/j.ejps.2011.09.012 Stegemann, 2012, Adherence Measurement Systems and Technology for oral medications in older patient populations, Eur Geriatr Med., 3, 254, 10.1016/j.eurger.2012.05.004 Sternberger-Rützel, 2012, Quality-by-design: concept for the proof-of-principle testing regarding automated microdosing, Pharm. Ind., 74, 145 St. Gallen Report, 2006. International benchmarking study: operational Excellence in the Pharmaceutical Industry. University of St. Gallen & APV, 2006. Taplin, 1948, Prevention of postoperative pulmonary infection, JAMA, 138, 4, 10.1001/jama.1948.02900010006002 Thalberg, 2012, Modeling dispersion of dry powders for inhalation. The concept of total fines, cohesive energy and interaction parameters, Int. J. Pharm., 427, 224, 10.1016/j.ijpharm.2012.02.009 Thorsson, 1994, Lung deposition of budesonide from Turbohaler is twice that from a pressurized metered-dose inhaler P-MDI, Eur. Respir. J., 7, 1839, 10.1183/09031936.94.07101839 Tronde, 2008, Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD, J. Clin. Pharmacol., 48, 1300, 10.1177/0091270008322122 United Nations General Assembly resolution 65/1, 2010. <http://www.who.int/nmh/publications/un_resolution65_1/en/>. 2008, World Health Organization ISBN Virchow, 2008, Importance of inhaler devices in the management of airways disease, Respir. Med., 102, 10, 10.1016/j.rmed.2007.07.031 Weers, 2010, Pulmonary formulations: what remains to be done?, J. Aerosol. Med. Pulmonary Drug Del., 23 World Health Assembly resolution 52.19. May 24, 1999. WHO’s Revised Drug Strategy <http://www.who.int/phi/documents/en/>. World Health Organization, 2011. Guidelines for the programmatic management of drug-resistant tuberculosis: update 2011. ISBN 978 92 4 150158 3. Geneva, Switzerland. WHO. World Health Organization, 2010. The stop TB strategy. <http://www.who.int/tb/publications/2010/strategy_en.pdf>. Wyka, 2007, Comparison of two approaches for treating cascade impaction mass balance measurements, J. Aerosol. Med., 20, 236, 10.1089/jam.2007.0609 Young, 2005, The influence of dose on the performance of dry powder inhalation systems, Int. J. Pharm., 296, 26, 10.1016/j.ijpharm.2005.02.004 Young, 2008, Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery, J. Aerosol. Sci., 39, 82, 10.1016/j.jaerosci.2007.10.003 Zeng, 1998, The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro, Int. J. Pharm., 176, 99, 10.1016/S0378-5173(98)00300-7